Objective : We assessed the associations between FDG uptake in primary papillary thyroid carcinomas (PTCs) and clinicopathological features, including the BRAF V600E mutation, using quantitative and qualitative analyses of preoperative PET/CT data. 
| INTRODUCTION
Thyroid cancer is the most common endocrine neoplasm, and most are papillary thyroid carcinomas (PTCs). Although the prognosis is favourable, with a 5-years survival rate of 97.8%, some patients suffer from recurrent or progressing disease after surgery or from disease refractory to radioactive iodine therapy. 1, 2 Several studies have shown that pathological characteristics, such as tumour size, presence of extrathyroid extension and lymph node metastasis, are prognostic factors potentially influencing clinical outcomes. 3, 4 Additionally, the BRAF V600E mutation, the most common mutation in differentiated thyroid cancer, has been associated significantly with extrathyroid invasion, lymph node metastasis and tumour recurrence. [5] [6] [7] Recently, BRAF V600E mutation testing of primary PTC samples has become more popular, as a method to predict tumour aggressiveness.
[ 18 F]fluorodeoxyglucose (FDG) is a glucose analog that is transported into cells via glucose transporters (GLUT), which are considered critical for FDG influx into cells. The uptake of FDG by malignant cells has been reported to reflect their metabolism and has been related to biological features. 8 Unlike nonthyroid malignancies, PTCs
show widely varying levels of FDG uptake, from imperceptible to intense, and with no necessary correlation with GLUT1 or GLUT3. 9, 10 Recently, some studies have shown that the level of FDG uptake is significantly associated with clinicopathological features in patients with PTC. In particular, the BRAF V600E mutation status is an emerging factor associated with FDG uptake on PET/CT in patients with PTC. 11, 12 However, a definite relationship between clinicopathological characteristics and the prognostic relevance of FDG uptake remains to be undetermined. An understanding of the clinicopathological characteristics that may influence FDG uptake is necessary to evaluate the prognostic impact of preoperative PET/CT findings in patients with PTC.
We considered that certain clinicopathological factors and the BRAF V600E mutation status may influence FDG uptake in PET/ CT, an important prognostic parameter in patients with PTC. To our knowledge, while investigations regarding the relationship between clinicopathological characteristics and FDG accumulation have been performed, they have been based on quantitative or qualitative analyses alone. In this study, we sought to assess the association between FDG uptake in primary PTCs and clinicopathological features, including the BRAF V600E mutation status, using both quantitative and qualitative analyses of preoperative PET/CT data.
| MATERIALS AND METHODS

| Patient population
In total, 1499 patients with PTC underwent total thyroidectomy at our institution between January 2009 and January 2011. Of them, we retrospectively reviewed data from 137 patients who underwent preoperative PET/CT within 6 months before total thyroidectomy. We excluded 31 patients with data inappropriate for the analysis for the following reasons: referrals to other clinics, poor-quality PET/CT data and uncontrolled diabetes mellitus. Finally, in total, 106 patients with PTC were included in this study. Clinicopathological parameters were obtained through an electronic medical record review and were correlated with PET/CT findings.
The study was approved by the institutional review board in the hospital. The requirement for written informed consent was waived because of the study's retrospective nature.
| FDG PET/CT
All patients fasted for at least 6 hours before PET/CT. 
| PET/CT analysis
All PET/CT images were transferred to a workstation using a fusion software system (Mirada Medical, Oxford, UK) that provided multiplanar reformatted images and displayed PET images after at- 
| Clinicopathological characteristics
Pathological characteristics were evaluated in the surgical specimens obtained from the total thyroidectomy by an experienced pathologist: primary tumour size, subtype, presence of capsular invasion, extrathyroid extension, multifocality and lymph node metastasis. At the time of preoperative PET/CT scanning, distant metastasis was evaluated. When assessable, data regarding the BRAF V600E mutation from surgical specimens were collected. BRAF V600E mutation analysis was performed as follows. The BRAF V600E mutation was analysed by Sanger sequencing, as described previously. 13 Genomic DNA was isolated from manually dissected 10-μm-thick paraffin waxembedded tissue sections using the QIAamp DNA Mini kit (Qiagen, Hilden, Germany). Exon 15 of the BRAF gene was amplified by PCR using forward (5′-TCATAATGCTTGCTCTG ATAGGA-3′) and reverse primers (5′-GGCCAAAAATT TAATCAGTGGA-3′). PCR products were purified according to the manufacturer's protocol and sequenced directly using the same primers used for amplification and the ABI-PRISM BigDye Terminator (ver. 3.1) cycle sequencing kit (Applied Biosystems, Foster, CA, USA) on the Applied Biosystems 3730xl DNA Analyzer. 
| Statistical analysis
| RESULTS
| Clinicopathological characteristics
| Correlation between SUVmax and clinicopathological variables
The mean PTC SUVmax was 5.1 (median 3.6, range 0.8-25.4).
SUVmax was significantly higher in primary tumours of size >1 cm than in those ≤1 cm (6.6±5. 
| Subgroup analysis of patients with FDG-avid PTCs vs non-FDG-avid PTCs
Of the 106 patients, 71 (67%) had FDG-avid PTCs and 35 (33%) non-FDG-avid PTCs. 
| Subgroup analysis of patients with PTCs ≤1 cm vs >1 cm
Among the 106 patients, 57 (54%) had PTCs >1 cm and 49 (46%) PTCs ≤1 cm. In the PTC >1 cm subgroup, multivariate analysis showed that sex, tumour size and BRAF V600E mutation status were significantly associated with the PTC SUVmax. In the PTC ≤1 cm subgroup, multivariate analysis showed no significant association between the BRAF V600E mutation status and PTC SUVmax (Table 5 ).
| DISCUSSION
In 2015, the American Thyroid Association published guidelines for cancer management and provided a clinicopathological risk stratification system to estimate prognosis for patients with differentiated thyroid cancer.
14 Although most patients with PTC survive >10 years without tumour recurrence and have a disease-specific mortality rate of <1%, locoregional recurrence or distant metastasis was found in a proportion of patients with PTC with invasive pathological characteristics, such as extrathyroid extension and lymph node metastasis.
3,4
We conducted an observational study using retrospectively collected data from patients with PTC at a single centre to investigate the clinical value of preoperative PET/CT as a candidate predictor of local tumour invasiveness. There has been controversy regarding the association between FDG uptake of the primary tumour on PET/CT and clinicopathological features related to tumour aggressiveness. 
T A B L E 3 The clinicopathological factors according to FDG avidity
Several investigators have shown that a larger tumour size, the presence of extrathyroid extension and lymph node metastasis are more likely to be associated with PTC FDG positivity. 17, 18 In contrast, others have found no correlation between the SUVmax in primary PTC and the presence of multifocality, extrathyroid extension of primary PTC or lymph node metastasis. 16 In a univariate analysis, we showed that
PTCs of larger size with extrathyroid extension and the BRAF V600E mutation were associated with a higher PTC SUVmax. The present study is consistent with the hypothesis that PET/CT can provide useful information regarding the SUVmax and clinicopathological features related to aggressive PTC.
We performed visual assessments and classified patients according to PTC FDG avidity. As shown in Table 3 20 In the present study, the proportion of patients with PTC harbouring the BRAF V600E mutation was 82.1%, similar to that of >70% of patients with PTC in Korea reported previously. 21, 22 In contrast, research in Western countries has shown lower frequencies of the BRAF V600E mutation in patients with PTC. 23, 24 This may be associated with different genetic backgrounds, possibly related to molecular genotypes for the other oncogenic mutations, although this remains unclear. 25, 26 Limitations of the present study stem from the selection bias induced by enrolling patients who underwent PET/CT before total thyroidectomy, resulting in a small population of low-risk patients.
Additionally, correlational data with other molecular genotypes in patients with a poor prognosis were lacking in the present study. We are planning further molecular analyses to explore the biological behaviour of malignant thyroid tumours. Although we did not investigate GLUT expression, we suggest that the relationship between the BRAF V600E mutation status and GLUT expression may be associated with the molecular features of glucose metabolism in malignant cells. FDG uptake on PET/CT would yield additional information on tumour aggression and is currently under investigation using biological markers such as GLUTs. Lastly, another limitation is that because of constraints on follow-up, we could not analyse tumour recurrence either via PET/CT or clinicopathologically. Further studies are required to assess the clinical utility of PET/CT data in a large number of patients with follow-up data over 5-10 years.
In conclusion, the present study showed a significant association between the SUVmax and clinicopathological characteristics in PTC and suggested clinical implications derived from the quantitative analysis. PET/CT may play an important role in determining the association with molecular biomarkers, such as the BRAF V600E mutation.
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